# Leuko Labs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/leuko-labs

- Industry: Medical Devices & Equipment
- Headquarters: Boston, US
- Website: www.leuko.io
- Total disclosed funding: $6.8M
- Latest round: Series A (Jul 22, 2022)
- Investors on record: 5

## About

Leuko Labs, Inc. is a biotechnology company focused on developing advanced diagnostic technologies, particularly for assessing white blood cell levels to aid healthcare providers and patients in managing infection risks.Founded in 2017 and headquartered in Boston, US, Leuko Labs, Inc. specializes in innovative diagnostics, notably their product PointCheck™. The company was co-founded by Alvaro Sanchez-Ferro, Aurélien Bourquard, Carlos González, and Ian Butterworth. In July 2022, the firm raised USD 5 million in Series A funding led by Health Technology Holding, with participation from Good Growth Capital, IAG Capital Partners, and Nina Capital, bringing their total amount raised to USD 5 million and current company valuation to USD 18.856 mn.Leuko Labs, Inc. specializes in innovative diagnostic technologies, focusing primarily on their flagship product, PointCheck™, a portable, non-invasive test designed to evaluate white blood cell levels. This device utilizes light to image blood cells flowing through the capillaries in the skin surrounding the fingernail, enabling a rapid assessment of white blood cell counts within one minute. Targeted primarily at chemotherapy patients who are at an increased risk of infection due to low white blood cell levels, the product is relevant in healthcare settings where monitoring immune status is critical, facilitating timely alerts for elevated infection risks and enabling early intervention.Leuko Labs, Inc. generates revenue through a business-to-consumer model where healthcare providers and patients purchase the PointCheck™ device for monitoring white blood cell levels. Revenue streams may include direct sales to medical facilities and partnerships with healthcare organizations integrating the device into patient management protocols. The financial model indicates potential recurring revenue through both one-time purchases of devices and possibly subscription models for ongoing services or updates.Leuko Labs, Inc. plans to utilize the USD 5 million raised in July 2022 to support its clinical trials. The company aims to expand its market presence, particularly within the United States and Europe, focusing on regions with significant healthcare infrastructure. Future developments include upcoming iterations of the PointCheck™ technology designed to enhance user experience and accuracy, though specific release dates are not provided.

## Funding rounds

- Series A, Jul 22, 2022, $5M — Good Growth Capital, Nina Capital, IAG Capital Partners, Health Technology Holding
- Seed, Jul 17, 2019, $1.8M — Pegasus Tech Ventures, Good Growth Capital, Nina Capital
- Seed, Mar 20, 2019 — Pegasus Tech Ventures

## Investors

- Pegasus Tech Ventures (https://capitalatlas.ai/funds/pegasus-tech-ventures) — Seed
- Good Growth Capital (https://capitalatlas.ai/funds/good-growth-capital) — Seed, Series A
- Nina Capital (https://capitalatlas.ai/funds/nina-capital) — Seed, Series A
- IAG Capital Partners (https://capitalatlas.ai/funds/iag-capital-partners) — Series A
- Health Technology Holding (https://capitalatlas.ai/funds/health-technology-holding) — Series A